In the preclinical studies using an antisense approach, downregulation of BCL-2 or BCL-XL resulted in glioma cell death and sensitization to the effects of chemotherapy and radiotherapy (Guensberg et al., 2002; Jiang et al., 2003; Zhu et al., 2003). This evidence concerns the gene BCL2L1 and glioma.